NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) — Financial Flexibility Index
NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) has a Financial Flexibility Index of -0.56x as of September 2025. Free cash flow of $-32.73 Million (operating CF $-32.77 Million minus capex $42.00K) represents -1% of total liabilities ($58.36 Million). Check NAMS cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
NewAmsterdam Pharma Company N.V. Ordinary Shares Financial Flexibility Index (2020–2024)
Historical Financial Flexibility Index trend for NewAmsterdam Pharma Company N.V. Ordinary Shares across 5 annual periods. For the full cash flow conversion analysis, see cash flow conversion of NewAmsterdam Pharma Company N.V. Ordinar.
Annual Financial Flexibility Index for NewAmsterdam Pharma Company N.V. Ordinary Shares (2020–2024)
Year-by-year free cash flow to debt coverage for NewAmsterdam Pharma Company N.V. Ordinary Shares. Explore NAMS cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -1.47x | $-157.89 Million | $-158.56 Million | $107.12 Million | ▲ +38.7% |
| 2023 | -2.41x | $-141.19 Million | $-141.22 Million | $58.70 Million | ▼ -1170.0% |
| 2022 | 0.22x | $10.89 Million | $10.66 Million | $48.43 Million | ▲ +108.7% |
| 2021 | -2.60x | $-29.49 Million | $-29.51 Million | $11.36 Million | ▼ -339.5% |
| 2020 | -0.59x | $-7.33 Million | $-7.34 Million | $12.41 Million | — |